<DOC>
	<DOC>NCT02116660</DOC>
	<brief_summary>To evaluate changes in renal function, efficacy, and safety when switching from a combination of tenofovir/emtricitabine (TDF/FTC) plus a protease inhibitor/ritonavir (PI/r) to a combination of raltegravir (MK-0518) plus nevirapine plus lamivudine in human immunodeficiency virus (HIV)-1 participants with suppressed viremia and impaired renal function.</brief_summary>
	<brief_title>Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Male, or nonpregnant, nonbreastfeeding female No previous history of virological failure No previous exposure to nonnucleoside reverse transcriptase inhibitors or integrase inhibitors No previous history of intolerance to lamivudine At least 2 documented plasma HIV1 RNA &lt;50 copies/mL and no HIV1 &gt;50 copies/mL in the 12 months before screening Receiving the same protease inhibitor/ritonavir plus tenofovir/emtricitabine combination for at least the 6 months before screening Has no major International Antiviral Society (IAS)USA mutations on genotype testing performed before starting antiretroviral treatment Sexuallyactive participants and their partners of childbearing potential agree to use a medically acceptable method of contraception from 2 weeks before Day 1 and for at least 6 months after the last dose of study drug (postmenopausal women are not required to use contraception; sexuallyactive male participants with a female partner of childbearing potential must provide written informed consent to information regarding any pregnancy) Positive for hepatitis B surface antigen (HBsAg+) or anticipated need for hepatitis C virus treatment Liver cirrhosis Has a history of diabetes mellitus, defined as initiation of antidiabetic treatment or verification of diabetes in a case report form Has any cancer, excluding stable Kaposi Sarcoma Allergy or sensitivity to the investigational product or excipients Female participant who is nursing Female participant who is pregnant or intends to become pregnant Has an active Acquired Immunodeficiency Syndrome (AIDS)defining event except stable Kaposi Sarcoma or HIV Wasting Syndrome Received any investigational drug within 30 days before screening Participated in any other clinical trial within 30 days before signing informed consent for the current trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>